Clinical Trial: Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07864480) titled 'Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.' on July 20.

Brief Summary: In Prolifertive Diabetic Retinopathy eyes with bleeding known as vitreous hemorrhage (VH) requiring a surgical procedure to remove the vitreous, called a vitrectomy, we will determine if the benefit and safety of adding a small implant that will be filled with medication called Susvimo is better with limited laser treatment.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Proliferative Diabetic Retinopathy (DR)...